These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35589418)

  • 1. Etiopathogenesis of kidney disease in minority populations and an updated special focus on treatment in diabetes and hypertension.
    Umeukeje EM; Washington JT; Nicholas SB
    J Natl Med Assoc; 2022 Jun; 114(3S2):S3-S9. PubMed ID: 35589418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
    Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
    Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrology co-management versus primary care solo management for early chronic kidney disease: a retrospective cross-sectional analysis.
    Samal L; Wright A; Waikar SS; Linder JA
    BMC Nephrol; 2015 Oct; 16():162. PubMed ID: 26458541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.
    Mende CW
    Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations.
    Shubrook JH; Neumiller JJ; Wright E
    Postgrad Med; 2022 May; 134(4):376-387. PubMed ID: 34817311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes.
    Vart P; Vaduganathan M; Jongs N; Remuzzi G; Wheeler DC; Hou FF; McCausland F; Chertow GM; Heerspink HJL
    Clin J Am Soc Nephrol; 2022 Dec; 17(12):1754-1762. PubMed ID: 36414316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis from the EMPA-REG OUTCOME
    Mayer GJ; Wanner C; Weir MR; Inzucchi SE; Koitka-Weber A; Hantel S; von Eynatten M; Zinman B; Cherney DZI
    Kidney Int; 2019 Aug; 96(2):489-504. PubMed ID: 31142441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular disease and its relationship with chronic kidney disease.
    Liu M; Li XC; Lu L; Cao Y; Sun RR; Chen S; Zhang PY
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(19):2918-26. PubMed ID: 25339487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.
    Weir MR; McCullough PA; Buse JB; Anderson J
    Am J Nephrol; 2020; 51(4):276-288. PubMed ID: 32172239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.
    Fried L; Schmedt N; Folkerts K; Bowrin K; Raad H; Batech M; Kovesdy C
    Nephrol Dial Transplant; 2023 Feb; 38(3):630-643. PubMed ID: 35389468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipping Status, Ambulatory Blood Pressure Control, Cardiovascular Disease, and Kidney Disease Progression: A Multicenter Cohort Study of CKD.
    Borrelli S; Garofalo C; Gabbai FB; Chiodini P; Signoriello S; Paoletti E; Ravera M; Bussalino E; Bellizzi V; Liberti ME; De Nicola L; Minutolo R
    Am J Kidney Dis; 2023 Jan; 81(1):15-24.e1. PubMed ID: 35709922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and predictors of chronic kidney disease among Ghanaian patients with hypertension and diabetes mellitus: A multicenter cross-sectional study.
    Tannor EK; Sarfo FS; Mobula LM; Sarfo-Kantanka O; Adu-Gyamfi R; Plange-Rhule J
    J Clin Hypertens (Greenwich); 2019 Oct; 21(10):1542-1550. PubMed ID: 31465141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study.
    Chu L; Fuller M; Jervis K; Ciaccia A; Abitbol A
    Clin Ther; 2021 Sep; 43(9):1558-1573. PubMed ID: 34426012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological strategies for kidney function preservation: are there differences by ethnicity?
    Lakkis J; Weir MR
    Adv Ren Replace Ther; 2004 Jan; 11(1):24-40. PubMed ID: 14730536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD.
    Mottl AK; Alicic R; Argyropoulos C; Brosius FC; Mauer M; Molitch M; Nelson RG; Perreault L; Nicholas SB
    Am J Kidney Dis; 2022 Apr; 79(4):457-479. PubMed ID: 35144840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex differences in hypertension-related renal and cardiovascular diseases in Italy: the I-DEMAND study.
    Muiesan ML; Ambrosioni E; Costa FV; Leonetti G; Pessina AC; Salvetti M; Trimarco B; Volpe M; Pontremoli R; Deferrari G; Rosei EA
    J Hypertens; 2012 Dec; 30(12):2378-86. PubMed ID: 23137952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in The Netherlands.
    van Schoonhoven AV; Schöttler MH; Serné EH; Schrömbges PPG; Postma MJ; Boersma C
    J Med Econ; 2023; 26(1):547-553. PubMed ID: 36987694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A renaissance in the treatment of diabetic kidney disease, hypertension in chronic kidney disease, and beyond.
    Yahr J; Calle J; Taliercio JJ
    J Osteopath Med; 2021 Oct; 122(1):55-63. PubMed ID: 34648702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.